References
- Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. New Eng J of Med. 1994;330:585–91.
- Chen HS, Lipton SA. Mechanisms of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J Physiol. 1997;499:27–46.
- Rothsten JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009;65:S3–9.
- Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. New Eng J Med. 1992;326:1464–8.
- Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett. 2004;566:261–9.
- Murayama S, Mori H, Ihara Y, Suzuki K, Tomonaga M. Immunocytochemical and ultrastructural studies of lower motor neurons in amyotrophic lateral scelrosis. Ann Neurol. 1990;27:137–48.
- Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani, H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology. 2006;66:852–6.
- Jiminez FJJ, Hernanz A, Medina Acebron S. Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2005;111:1114–7.
- Sussmuth SD, Tumani H, Ecker D, Ludolph AC. Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci Letters. 2003;353:57–60.
- Wang R, Zhang D. Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur J Nuerosci. 2005;22:2376–80.
- Schonknecht P, Pantel J, Hartmann T, Werle E, Volkmann M, Essig G, . Cerebrospinal fluid tau levels in Alzheimer's disease are elevated compared with vascular dementia but do not correlate with measures of cerebral atrophy. Psychiatry Research. 2003;120:231–8.
- Quereshi M, Schoenfeld D, Cudkowicz, M. Disease progression in ALS has not changed in the past decade. AAN 2008 Poster presentation.
- Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, . Longitudinal stability of CSF tau levels in Alzheimer's disease patients. Biol Psychiatry. 1999;46:750–5.
- Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, . Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry. 2004;9:705–10.
- Paladino P, Valentino F, Piccoli T, Piccoli F, La Bella V. Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis. Eur J Neurol. 2009;16:257–61.
- Boylan K, Yang C, Crook J, Overstreet K, Heckman M, Wang Y, . Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) is blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem. 2009;111:1182–91.
- de Carvalho M, Pinto S, Costa J, Evangelista T, Ohana B, Pinto A. A randomized, placebo controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11:456–60.